ENDPOINTS

Sanofi makes $470M move for Vigil's Alzheimer's drug, while another asset returns to Amgen

Sanofi plans to buy Vigil Neuroscience, a drugmaker advancing TREM2 agonism programs that derive from Amgen. The French pharma will acquire Vigil for its oral small molecule TREM2 project, dubbed VG-3927, that is on tap ...

May 22, 2025 - 09:24
 0
Sanofi makes $470M move for Vigil's Alzheimer's drug, while another asset returns to Amgen
Sanofi plans to buy Vigil Neuroscience, a drugmaker advancing TREM2 agonism programs that derive from Amgen. The French pharma will acquire Vigil for its oral small molecule TREM2 project, dubbed VG-3927, that is on tap ...
Read More

Tags:

Previous Article

Weary parents shouldn't miss this science-backed guide to raising kids

Next Article

Bored with manicured lawns, some homeowners adopt No Mow May all year long

Related Posts

Dutch biotech Azafaros gets $146M for Phase 3 trials in three metabolic disorders

Dutch biotech Azafaros gets $146M for Phase 3 trials in...

May 13, 2025  0

Top RFK Jr. advisor dares drugmakers over threats to drop manufacturing promises

Top RFK Jr. advisor dares drugmakers over threats to dr...

May 15, 2025  0

Biohaven stock sinks on three-month delay for neuro drug's FDA approval decision

Biohaven stock sinks on three-month delay for neuro dru...

May 15, 2025  0